Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status

BioArctic Sweden

View original content:https://www.prnewswire.co.uk/news-releases/rolling-sbla-initiated-to-the-us-fda-for-leqembi-iqlik-lecanemab-irmb-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-fast-track-status-302544535.html